221 related articles for article (PubMed ID: 23062917)
21. Unusual complication of vemurafenib treatment of metastatic melanoma: exacerbation of acantholytic dyskeratosis complicated by Kaposi varicelliform eruption.
Gupta M; Huang V; Linette G; Cornelius L
Arch Dermatol; 2012 Aug; 148(8):966-8. PubMed ID: 22911209
[No Abstract] [Full Text] [Related]
22. Tamoxifen-induced eccrine squamous syringometaplasia.
Teoh DC; Aw DC; Jaffar H; Ling W; Yong WP; Lee YS; Choo SN; Tan KB
J Cutan Pathol; 2012 May; 39(5):554-7. PubMed ID: 22390276
[TBL] [Abstract][Full Text] [Related]
23. Eccrine squamous syringometaplasia in intertriginous areas.
Valks R; Buezo GF; Daudén E; Fraga J; García-Díez A
Br J Dermatol; 1996 May; 134(5):984-6. PubMed ID: 8736357
[No Abstract] [Full Text] [Related]
24. [Eccrine squamous syringometaplasia from chemotherapy extravasation].
Bordel MT; Miranda A
Actas Dermosifiliogr; 2005 Sep; 96(7):462-4. PubMed ID: 16476276
[TBL] [Abstract][Full Text] [Related]
25. Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma.
Alonso-Castro L; Ríos-Buceta L; Vano-Galvan S; Moreno C; Soria-Rivas A; Jaén P
J Am Acad Dermatol; 2013 Jul; 69(1):e28-9. PubMed ID: 23768302
[No Abstract] [Full Text] [Related]
26. BRAFi-associated panniculitis - an emerging side effect with a variable histological picture: report of two cases and review of the literature.
Ferreira J; Toda-Brito H; Moura MC; Sachse MF; Costa-Rosa J
J Cutan Pathol; 2017 Mar; 44(3):307-309. PubMed ID: 27976808
[No Abstract] [Full Text] [Related]
27. Sarcoidosis associated with vemurafenib.
Adam A; Thomas L; Bories N; Zaharia D; Balme B; Freymond N; Dalle S
Br J Dermatol; 2013 Jul; 169(1):206-8. PubMed ID: 23834124
[No Abstract] [Full Text] [Related]
28. Vemurafenib-induced DRESS.
Wenk KS; Pichard DC; Nasabzadeh T; Jang S; Venna SS
JAMA Dermatol; 2013 Oct; 149(10):1242-3. PubMed ID: 23986488
[No Abstract] [Full Text] [Related]
29. Fanconi syndrome induced by vemurafenib: a new renal adverse event.
Denis D; Franck N; Fichel F; Levi C; Dupin N
JAMA Dermatol; 2015 Apr; 151(4):453-4. PubMed ID: 25494458
[No Abstract] [Full Text] [Related]
30. Neutrophilic eccrine hidradenitis in two patients treated with BRAF inhibitors: a new cutaneous adverse event.
Herms F; Franck N; Kramkimel N; Fichel F; Delaval L; Laurent-Roussel S; Carlotti A; Avril MF
Br J Dermatol; 2017 Jun; 176(6):1645-1648. PubMed ID: 28005274
[TBL] [Abstract][Full Text] [Related]
31. Lupus erythematosus-like skin eruption after vemurafenib therapy.
Reinholz M; Berking C; Hermans C; Ruzicka T; Braun-Falco M
J Am Acad Dermatol; 2014 Oct; 71(4):e159-60. PubMed ID: 25219748
[No Abstract] [Full Text] [Related]
32. Toxic erythema of chemotherapy: a useful clinical term.
Bolognia JL; Cooper DL; Glusac EJ
J Am Acad Dermatol; 2008 Sep; 59(3):524-9. PubMed ID: 18694683
[No Abstract] [Full Text] [Related]
33. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma.
Anker CJ; Ribas A; Grossmann AH; Chen X; Narra KK; Akerley W; Andtbacka RH; Noyes RD; Shrieve DC; Grossmann KF
J Clin Oncol; 2013 Jun; 31(17):e283-7. PubMed ID: 23650406
[No Abstract] [Full Text] [Related]
34. Antineoplastic chemotherapy, sweat, and the skin.
Horn TD
Arch Dermatol; 1997 Jul; 133(7):905-6. PubMed ID: 9236531
[No Abstract] [Full Text] [Related]
35. Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.
Lheure C; Kramkimel N; Franck N; Laurent-Roussel S; Carlotti A; Queant A; Goldwasser F; Avril MF; Dupin N
Dermatology; 2015; 231(4):378-84. PubMed ID: 26452227
[TBL] [Abstract][Full Text] [Related]
36. Cutaneous side effects of vemurafenib: a case report and discussion.
Shea SM; Boyd K; Patterson J
Wien Med Wochenschr; 2013 Aug; 163(15-16):376-9. PubMed ID: 23824179
[TBL] [Abstract][Full Text] [Related]
37. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.
Alloo A; Garibyan L; LeBoeuf N; Lin G; Werchniak A; Hodi FS; Flaherty KT; Lawrence DP; Lin JY
Arch Dermatol; 2012 Mar; 148(3):363-6. PubMed ID: 22431777
[TBL] [Abstract][Full Text] [Related]
38. Eccrine squamous syringometaplasia secondary to cutaneous extravasation of docetaxel: report of three cases.
Gallo E; Llamas-Velasco M; Navarro R; Fraga J; García-Diez A
J Cutan Pathol; 2013 Mar; 40(3):326-9. PubMed ID: 23170995
[TBL] [Abstract][Full Text] [Related]
39. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
[No Abstract] [Full Text] [Related]
40. Papular Clear Cell Hyperplasia of the Eccrine Duct: A Precursor Lesion of Clear Cell Syringoma?
Alonso-Riaño M; Cámara-Jurado M; Garrido MC; Rodríguez-Peralto JL
Am J Dermatopathol; 2015 Sep; 37(9):701-3. PubMed ID: 26291420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
